Skip to content
Black Friday — 30% OFFFree shipping on orders of A$99 or more
  1. Home
  2. Hormonal Health & Growth
  3. Tamoxifen (20mg/capsule), 60 Capsules
Hormonal Health

Tamoxifen (20mg/capsule), 60 Capsules

Tamoxifen is a triphenylethylene-class selective estrogen receptor modulator (SERM) that exhibits ligand-dependent interactions with estrogen receptors ERα and ERβ.

Presentation: Tamoxifen (20mg/capsule), 60 Capsules.

Illustrative packaging generated with AI.

Original price was: A$111.95.Current price is: A$78.37.

Currently unavailable in Australia

Ask an advisor
An advisor contacts you and the partner pharmacy checks whether and how it can proceed. A valid prescription, or an assessment through an authorised telemedicine service, may be required.
  • Partner pharmacy
  • Personal assistance
  • Discreet delivery
  • Presentation
    Tamoxifen (20mg/capsule), 60 Capsules

Shipping & Delivery

  • Normally dispatched within 24 hours of payment confirmation.
  • USPS Regular Shipping · A$11.95 · Approx. 3–5 business days
  • FedEx 2 Days Delivery · A$28.99 · Approx. 2 business days
  • FedEx Overnight Delivery · A$40.99 · Approx. 1 business day

For laboratory research only.

Not for human or veterinary use.

Composition and product details

Overview

Tamoxifen is a triphenylethylene-class selective estrogen receptor modulator (SERM) that exhibits ligand-dependent interactions with estrogen receptors ERα and ERβ. Experimental investigations have demonstrated that tamoxifen induces distinct receptor conformations that influence co-regulator recruitment, resulting in differential transcriptional activity across estrogen receptor signaling systems.

Its well-characterized pharmacology has made it a benchmark compound for studies of estrogen receptor modulation, ligand-receptor interactions, receptor conformational dynamics, nuclear receptor signaling, and transcriptional regulation.

Tamoxifen is also widely utilized in inducible CreERT2 systems, where ligand-dependent activation of modified estrogen receptor domains enables controlled recombination in genetic research models.

Research applications include ERα/ERβ pharmacology, SERM mechanism investigation, co-regulator recruitment studies, inducible recombination systems, and comparative analyses of selective estrogen receptor modulators.

  • High Purity – 99% Purity Guaranteed
  • Independently Lab Tested
  • Research Grade Quality
  • For Laboratory Research Use Only

Properties

Chemical Formula C26H29NO
Synonyms Nolvadex (trade name), ICI-46474, TMX, (Z)-Tamoxifen
Molar Mass 371.52 g/mol
CAS Number 10540-29-1
PubChem CID 2733526
Total Compound Content 1,200 mg (20 mg per capsule)
Shelf Life 36 months

Research

Tamoxifen ((Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine) is a triphenylethylene-class selective estrogen receptor modulator (SERM) with extensively characterized interactions at ERα and ERβ. Experimental investigations have demonstrated that tamoxifen induces distinct estrogen receptor conformations that influence co-regulator recruitment and downstream transcriptional activity. Its pharmacological profile has made it a benchmark compound for studies of estrogen receptor signaling, ligand-receptor interactions, nuclear receptor conformational dynamics, transcriptional regulation, and selective receptor modulation. Tamoxifen and its metabolites are frequently utilized in investigations of estrogen receptor pharmacology, receptor-cofactor interactions, and structure-function relationships within nuclear receptor signaling systems. It is also widely employed in inducible CreERT2 recombination systems, where ligand-dependent activation of modified estrogen receptor domains enables controlled genetic recombination in experimental models. Independently third-party HPLC-tested; COA available per batch.

FAQ

What is tamoxifen’s role in CreERT2 conditional recombination systems?

Tamoxifen is widely utilized in CreERT2-based inducible recombination systems, which employ a fusion protein consisting of Cre recombinase linked to a modified estrogen receptor ligand-binding domain. In the absence of ligand binding, the fusion protein remains functionally inactive.

Upon tamoxifen-mediated activation, CreERT2 undergoes conformational changes that permit recombinase activity at loxP recognition sites, enabling controlled genetic recombination. This mechanism has made tamoxifen an indispensable tool for studies requiring inducible and temporally regulated gene modification in experimental systems.

How do tamoxifen metabolites differ from the parent compound in estrogen receptor research?

Tamoxifen undergoes extensive metabolic conversion to several active metabolites, including endoxifen and 4-hydroxytamoxifen, which exhibit substantially greater affinity for estrogen receptors than the parent molecule.

These metabolites are frequently investigated in studies of estrogen receptor binding, ligand-receptor interactions, receptor conformational dynamics, and transcriptional regulation. Their enhanced receptor affinity makes them valuable tools for comparative analyses of estrogen receptor pharmacology and SERM-associated signaling mechanisms.

What distinguishes tamoxifen from other selective estrogen receptor modulators in research applications?

Tamoxifen is characterized by its extensively studied interactions with ERα and ERβ, its well-defined effects on receptor conformation and co-regulator recruitment, and its broad utility in both receptor pharmacology and inducible recombination systems. These properties make it a benchmark compound for investigations of selective estrogen receptor modulation, nuclear receptor signaling, transcriptional regulation, ligand-dependent receptor activity, and comparative studies of SERM pharmacology.

Capsule excipients are not specified in the available product documentation.